CLR 131, Cellectar Biosciences’ lead experimental candidate, resulted in a 40% response rate among people with multiple myeloma who failed to respond to three treatment modalities, according to additional data from the CLOVER-1 clinical trial. These triple-refractory patients, who previously failed to respond to at least one immunomodulatory treatment, one proteasome inhibitor, and one anti-CD38 antibody, had received a total CLR 131 dose of 60 millicurie (mCi, a unit of radioactivity) or greater. “We remain…
You must be logged in to read/download the full post.
The post CLR 131 Elicits Promising Response Rates in Triple-refractory Multiple Myeloma Trial appeared first on BioNewsFeeds.